BRD4 and prostate carcinoma: In the same way, prostate tumoroids have revealed that prostate cancer-associated SPOP mutations confer resistance to BET inhibitors through the stabilization of BRD4 (Dai et al., 2017), enabling a deeper understanding of how prostate cancers of certain patients respond to treatment according to their genetic lesions.